Masimo price target raised to $166 from $145 at BTIG

BTIG analyst Marie Thibault raised the firm’s price target on Masimo to $166 from $145 and keeps a Buy rating on the shares. Investor focus has shifted to what the company’s separation of its consumer business could look like, and while there are still unknowns to the Masimo story, some investors could come off the sidelines gradually in anticipation of a clean, standalone Healthcare business with improving EBIT margin and the ability to generate strong and consistent free cash flow, the analyst tells investors in a research note.